anti-il-18bp monoclonal antibody gs-0321
Generic: Anti-IL-18BP Monoclonal Antibody GS-0321
anti-il-18bp monoclonal antibody gs-0321: 1 clinical trial tracked.
anti-il-18bp monoclonal antibody gs-0321 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-il-18bp monoclonal antibody gs-0321, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (1)
A First-in-Human, Phase 1 Dose Escalation and Dose Expansion Trial to Assess the Safety and Tolerability of COM503 as Monotherapy and in Combination Therapy in Participants With Advanced Solid Malignancies
Primary endpoint: To evaluate the safety profile of COM503 as monotherapy in participants with advanced malignancies.
Interventionalopen200 targetStarted 2025-01Completion 2027-1111 sites · Israel, United StatesCompugen Ltd